We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Ambulatory Medical Assistance (AMA) programme during active‐phase treatment in patients with haematological malignancies: A cost‐effectiveness analysis.
- Authors
Michallet, Anne‐Sophie; Malartre, Stephanie; Vignaud, Elodie; Bocquet, Alexiane; Sontag, Pascale; Galvez, Christelle; Blay, Jean‐Yves; Heudel, Pierre; Vimont, Alexandre; Blachier, Martin; Ferrua, Marie; Minvielle, Etienne; Mir, Olivier
- Abstract
Context: The need for patient navigator is growing, and there is a lack of cost evaluation, especially during survivorship. Objective: The objective of this study is to evaluate the cost‐effectiveness of an Ambulatory Medical Assistance (AMA) programme in patients with haematological malignancies (HM). Design A cost‐effectiveness analysis of the AMA programme was performed compared to a simulated control arm. Setting: An interventional, single‐arm and prospective study was conducted in a French reference haematology–oncology centre between 2016 and 2020. Participants: Adult patients were enrolled with histologically documented malignant haematology, during their active therapy phase, and treated either by intravenous chemotherapy or oral therapy. Methods: An extrapolation of the effectiveness was derived from a similar nurse monitoring programme (CAPRI study). Cost effectiveness of the programme was evaluated through adverse events of Grade 3 or 4 avoided in different populations. Results: Included patient (n = 797) from the AMA programme were followed during 125 days (IQR: 0–181), and adverse events (Grade 3/4) were observed in 10.1% of patients versus 13.4% in the simulated control arm. The overall cost of AE avoided was estimated to €81,113, leading to an ICER of €864. Conclusion: The AMA programme was shown to be cost‐effective compared to a simulated control arm with no intervention.
- Subjects
FRANCE; ONCOLOGY nursing; RELATIVE medical risk; HEALTH services accessibility; CANCER chemotherapy; PATIENT-centered care; MEDICAL care costs; COMPARATIVE studies; PATIENT monitoring; HEMATOLOGIC malignancies; COST effectiveness; RESEARCH funding; DESCRIPTIVE statistics; ADVERSE health care events; SENSITIVITY &; specificity (Statistics); CANCER patient medical care; LONGITUDINAL method; ADULTS
- Publication
European Journal of Cancer Care, 2022, Vol 31, Issue 6, p1
- ISSN
0961-5423
- Publication type
Article
- DOI
10.1111/ecc.13709